Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains.

[1]  K. Shudo,et al.  Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure. , 2013, ACS medicinal chemistry letters.

[2]  A. Casini,et al.  Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights. , 2013, Journal of medicinal chemistry.

[3]  J. Gut,et al.  A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant Giardia lamblia , 2013, Antimicrobial Agents and Chemotherapy.

[4]  A. Klegeris,et al.  The biological activity of auranofin: implications for novel treatment of diseases , 2012, Inflammopharmacology.

[5]  S. Wölfl,et al.  On the biological properties of alkynyl phosphine gold(I) complexes. , 2012, Angewandte Chemie.

[6]  A. Casini,et al.  Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. , 2012, Journal of medicinal chemistry.

[7]  M. Arkin,et al.  A high throughput drug screen for Entamoeba histolytica identifies a new lead and target , 2012, Nature Medicine.

[8]  A. Wieczorek,et al.  Synthesis and biological activities of ferrocenyl derivatives of paclitaxel , 2012 .

[9]  Ismael Gracia,et al.  Luminescent di- and polynuclear organometallic gold(I)-metal (Au2, {Au2Ag}n and {Au2Cu}n) compounds containing bidentate phosphanes as active antimicrobial agents. , 2012, Chemistry.

[10]  A. Casini,et al.  Thiolato gold(I) complexes containing water-soluble phosphane ligands: a characterization of their chemical and biological properties. , 2011, Dalton transactions.

[11]  M. Gramiccia,et al.  A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition , 2011, Amino Acids.

[12]  S. Berners‐Price.  Gold-Based Therapeutic Agents: A New Perspective , 2011 .

[13]  A. Isab,et al.  Seleno-auranofin (Et3PAuSe-tagl): synthesis, spectroscopic (EXAFS, 197Au Mössbauer, 31P, 1H, 13C, and 77Se NMR, ESI-MS) characterization, biological activity, and rapid serum albumin-induced triethylphosphine oxide generation. , 2010, Inorganic chemistry.

[14]  A. Casini,et al.  Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies , 2010, Medicinal research reviews.

[15]  I. Ubarretxena-Belandia,et al.  Water Soluble Phosphane-Gold(I) Complexes. Applications as Recyclable Catalysts in a Three-component Coupling Reaction and as Antimicrobial and Anticancer Agents. , 2009, European journal of inorganic chemistry.

[16]  A. Casini,et al.  Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs , 2009 .

[17]  W. Self,et al.  Inhibition of Selenium Metabolism in the Oral Pathogen Treponema denticola , 2009, Journal of bacteriology.

[18]  R. Levine,et al.  Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct , 2009, JBIC Journal of Biological Inorganic Chemistry.

[19]  Anna V. Protasio,et al.  Platyhelminth Mitochondrial and Cytosolic Redox Homeostasis Is Controlled by a Single Thioredoxin Glutathione Reductase and Dependent on Selenium and Glutathione* , 2008, Journal of Biological Chemistry.

[20]  A. Casini,et al.  New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications , 2008, FEBS letters.

[21]  E. Davioud‐Charvet,et al.  Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.

[22]  A. Laguna,et al.  Tetrahydrothiophene)Gold(I) or Gold(III) Complexes , 2007 .

[23]  V. Gladyshev,et al.  Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein , 2006, Nucleic acids research.

[24]  R. Eisler.  Chrysotherapy: a synoptic review , 2003, Inflammation Research.

[25]  F. Novelli,et al.  Gold(I) complexes as antimicrobial agents. , 1999, Farmaco.

[26]  B. Gautheron,et al.  New potentially cytotoxic thiolatogold(I) complexes of 1,1'-bis(diphenylphosphino)ferrocene , 1996 .

[27]  A. Laguna,et al.  1,1'-Bis(diphenylphosphino)ferrocene (dppf) complexes of gold(I) and gold(III). Crystal structures of [(dppf)AuPPh3]ClO4.cntdot.CHCl3 and [(dppf)Au(.mu.-dppf)Au(dppf)](ClO4)2.cntdot.2CH2Cl2 , 1993 .

[28]  A. Becke.  Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[29]  H. Stoll,et al.  Energy-adjustedab initio pseudopotentials for the second and third row transition elements , 1990 .

[30]  A. Isab,et al.  GC-MS and /sup 17/O NMR tracer studies of Et/sub 3/PO formation from auranofin and H/sub 2//sup 17/O in the presence of bovine serum albumin: an in vitro model for auranofin metabolism , 1988 .

[31]  A. Becke,et al.  Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.

[32]  Michael Dolg,et al.  Energy‐adjusted ab initio pseudopotentials for the first row transition elements , 1987 .

[33]  D. Bennett,et al.  Solid-state structure and solution equilibria of cyano (triethylphosphine) gold(I) , 1986 .

[34]  K. Blocka.  Auranofin versus injectable gold. Comparison of pharmacokinetic properties. , 1983, The American journal of medicine.

[35]  G. P. Sollott,et al.  Unsymmetrical Tertiary Phosphines of Ferrocene by Friedel-Crafts Reactions. I. Ferrocenylphenylphosphines , 1963 .

[36]  Gottlieb Nl.  Pharmacology of auranofin: overview and update. , 1986, Scandinavian journal of rheumatology. Supplement.